Skip to main content

You do not inherit a cancer, you inherit an increased risk of developing a cancer.


Daphné t’Kint de Roodenbeke
Head of the Oncogenetic Clinic

The Oncogenetic Clinic, within the Prevention and Screening Clinic at the Jules Bordet Institute and in partnership with the Genetics Centre at the Université Libre de Bruxelles, uses the latest technology to study the impact of the genes involved in the development of certains cancers.

For the vast majority of cancers heredity is not a factor. Just 10% among certain types of cancer (breast, colon, pancreas, endometrium or melanoma, to cite the most important) relate to a hereditary syndrome, that is, a mutated gene transmitted from one generation to the next that increases the risk of developing a cancer for those individuals who inherit it. 

Research projects



Project 1

Phase III multicenter, randomised, double-blind trial, evaluating the effectiveness and tolerance of Olaparib versus placebo (control group) as an adjuvant treatment among patients carrying a germline mutation of the BRCA1/2 genes.

Projet 2

Precision 2: Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes. A Belgian Precision 2 study.
  • Project initiator : Daphné t’Kint de Roodenbeke
  • Collaboration(s) : Belgian Society of Medical Oncology (BSMO)
  • Financing or Support : Academic study

The team